`Prostaglandin Analog Drugs
`
`EXHIBIT 2040
`
`Drug
`
`Active Ingredient
`
`Approval Date
`
`Launch Date
`
`Discontinuation Date
`
`XALATAN®
`LUMIGAN® 0.03%
`TRAVATAN®
`TRAVATAN Z®
`LUMIGAN® 0.01%
`Latanoprost
`ZIOPTAN™
`RESCULA®
`Travoprost
`Bimatroprost 0.03%
`
`latanoprost
`bimatoprost
`travoprost
`travoprost
`bimatoprost
`latanoprost
`tafluprost
`unoprostone isopropyl
`travoprost
`bimatoprost
`
`6/1996
`3/2001
`3/2001
`9/2006
`8/2010
`3/2011
`2/2012
`12/2012
`3/2013
`2/2015
`
`Q3 1996
`Qi 2001
`Q1 2001
`Q4 2006
`Q4 2010
`Q1 2011
`Q1 2012
`Q1 2013
`Q2 2013
`Q2 2015
`
`-
`8/2012
`7/2010
`-
`-
`-
`-
`2/2015
`-
`-
`
`[QVIA; CVS/Caremark, Orange Book; SEC Filings
`Source:
`Note: RESCULA®is not a prostaglandin analog drug, but | understand thatit belongs to the same therapeutic
`category. RESCULA®was first launched in October 2000 and then relaunched in February 2013.
`
`CONFIDENTIAL-PROTECTIVE ORDER MATERIAL
`
`ALCON 2040
`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`